These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39299141)

  • 1. Financial incentives to increase engagement across the hepatitis C care cascade among people at risk of or diagnosed with hepatitis C: A systematic review.
    Shen C; Dawe J; Traeger MW; Sacks-Davis R; Pedrana AE; Doyle JS; Hellard ME; Stoové M
    Int J Drug Policy; 2024 Nov; 133():104562. PubMed ID: 39299141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study.
    Fathima P; Jones M; D'Souza R; Totterdell J; Andric N; Abbott P; Norman R; Howard K; Cheng W; Pedrana A; Doyle JS; Davies J; Snelling T
    Trials; 2024 Jun; 25(1):387. PubMed ID: 38886819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Project Integrating Financial Incentives into a Hepatitis C Testing and Treatment Model of Care at a Sexual Health Service in Cairns, Australia, 2020-2021.
    Dawe J; Gorton C; Lewis R; Richmond JA; Wilkinson AL; Pedrana A; Stoové M; Doyle JS; Russell D
    Viruses; 2024 May; 16(5):. PubMed ID: 38793681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
    Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis.
    Oru E; Trickey A; Shirali R; Kanters S; Easterbrook P
    Lancet Glob Health; 2021 Apr; 9(4):e431-e445. PubMed ID: 33639097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis.
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Valencia BM; Bajis S; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
    Lancet Gastroenterol Hepatol; 2022 May; 7(5):426-445. PubMed ID: 35303490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of reviews evaluating the effectiveness of financial incentives in changing healthcare professional behaviours and patient outcomes.
    Flodgren G; Eccles MP; Shepperd S; Scott A; Parmelli E; Beyer FR
    Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD009255. PubMed ID: 21735443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Financial arrangements for health systems in low-income countries: an overview of systematic reviews.
    Wiysonge CS; Paulsen E; Lewin S; Ciapponi A; Herrera CA; Opiyo N; Pantoja T; Rada G; Oxman AD
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011084. PubMed ID: 28891235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of summer programmes on the outcomes of disadvantaged or 'at risk' young people: A systematic review.
    Muir D; Orlando C; Newton B
    Campbell Syst Rev; 2024 Jun; 20(2):e1406. PubMed ID: 38873396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: A systematic review.
    Kronfli N; Linthwaite B; Kouyoumdjian F; Klein MB; Lebouché B; Sebastiani G; Cox J
    Int J Drug Policy; 2018 Jul; 57():95-103. PubMed ID: 29715590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis.
    Trickey A; Fajardo E; Alemu D; Artenie AA; Easterbrook P
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):253-270. PubMed ID: 36706775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incentives for increasing prenatal care use by women in order to improve maternal and neonatal outcomes.
    Till SR; Everetts D; Haas DM
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD009916. PubMed ID: 26671418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation.
    Schwarz T; Horváth I; Fenz L; Schmutterer I; Rosian-Schikuta I; Mårdh O
    Int J Drug Policy; 2022 Apr; 102():103588. PubMed ID: 35101667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interventions for acute hepatitis C infection.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011644. PubMed ID: 30521693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of financial incentives on the quality of health care provided by primary care physicians.
    Scott A; Sivey P; Ait Ouakrim D; Willenberg L; Naccarella L; Furler J; Young D
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008451. PubMed ID: 21901722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
    Hartwell D; Cooper K; Frampton GK; Baxter L; Loveman E
    Health Technol Assess; 2014 Oct; 18(65):i-xxii, 1-202. PubMed ID: 25350588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.